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An enzyme-linked immunosorbent assay to diagnose Chagas’ disease by a serological test was performed
with Trypanosoma cruzi recombinant antigens (JL8, MAP, and TcPo). High sensitivity (99.4%) and specificity
(99.3%) were obtained when JL8 was combined with MAP (JM) and tested with 150 serum samples from
chagasic and 142 nonchagasic individuals. Moreover, JM also diagnosed 84.2% of patients in the acute phase
of T. cruzi infection.
A serological test is the most reliable and practical method
for the diagnosis of Chagas’ disease, an illness that is caused by
the protozoan Trypanosoma cruzi and that affects millions of
people in Latin America (22). The risk of T. cruzi transmission
by transfusion in areas where Chagas’ disease is endemic is
assessed by performing at least two different tests to detect
specific antibodies (23, 25, 26). In countries where Chagas’
disease is not endemic, it is advisable to use serological tests on
persons born in or given blood transfusions in countries where
Chagas’ disease is endemic (8, 9, 12, 14, 27). The acute phase
of Chagas’ disease is rarely diagnosed, because it is often with-
out symptoms (22). Moreover, natural transmission by triato-
mine bugs is under control in some Latin American countries.
Furthermore, there is still a need for continuing epidemiolog-
ical surveillance in countries where transmission has not yet
been controlled (5, 22). Conventional serological tests for Cha-
gas (CSC tests) (e.g., indirect immunofluorescence [IIF], indi-
rect hemagglutination [IHA], and enzyme-linked immunosor-
bent assay [ELISA]) usually employ semipurified antigens
from the epimastigote form of T. cruzi. Consequently, CSC
tests yield relatively large numbers of inconclusive and false-
positive results (4, 19, 23, 25), mainly when a concomitant
infection, such as leishmaniasis, is present (4, 31), and the
sensitivities of CSC tests are far from ideal in the diagnosis of
the early acute phase of disease (3, 28, 30) or in patients with
low titers of anti-T. cruzi antibodies (31). This nonideal per-
formance may have social, legal, and economic implications.
To overcome these problems, several laboratories developed
new serodiagnostic tests using antigens from infective trypo-
mastigote forms (1, 28, 30) or a combination of T. cruzi recom-
binant proteins and/or synthetic peptides (4, 6, 7, 13, 20, 21, 24,
31).
The International Atomic Energy Agency organized a col-
laborative study to develop an ELISA with a mixture of T. cruzi
recombinant antigens for immunodiagnosis of the acute and
chronic phases of Chagas’ disease. In this study, we evaluated
the performance of three T. cruzi recombinant antigens (JL8,
MAP, and TcPo) with serum samples from patients living in six
Latin American countries (Table 1). Previous studies showed
that JL8 and TcPo react with immunoglobulin G (IgG) anti-
bodies of patients with chronic Chagas’ disease (15–18), and
assays with JL8 showed high sensitivity and specificity (4, 7, 13,
15–18). MAP is recognized by IgG antibodies from chronic and
acute chagasic patients (11; unpublished data).
Mixtures of recombinant antigens perform better than sin-
gle proteins. Several studies have shown that the use of a single
antigen in an assay does not confer the required sensitivity (4,
7, 16, 18, 21, 29, 31). In this study, the reactivities of recombi-
nant antigens, used singly or in different combinations, were
compared with the reactivities of the following tests: (i) CSC
tests (IIF, IHA, epi-ELISA [ELISA that uses semipurified
antigens from the epimastigote form of T. cruzi], and EAE-
ELISA [in-house ELISA that uses the epimastigote form of T.
cruzi]) (31); (ii) a test using a mixture of recombinant proteins
(BHF) developed for diagnosis of chronic cases (31); and (iii)
a Western blot assay that uses antigens from T. cruzi trypo-
* Corresponding author. Mailing address: Instituto de Medicina
Tropical de Sa˜o Paulo da Universidade de Sa˜o Paulo, Av. Dr. Ene´as de
Carvalho Aguiar 470, CEP 05403-000, Sa˜o Paulo, SP, Brazil. Phone:
55-113066 7015. Fax: 55-113088 5237. E-mail: eumezawa@usp.br.
449
mastigotes (TESA blot assay) (28, 31). The diagnostic perfor-
mance of ELISA with JL8, MAP, and TcPo antigens used
singly or in various combinations of two or three antigens was
evaluated first, using a panel of serum samples from 11 Bra-
zilian patients with the chronic phase of Chagas’ disease that
were positive by CSC tests. The optimal concentration of each
component was determined by cross-titration: the optimal se-
rum and conjugate dilutions were determined to be 1:50 and
1:6,000, respectively. Microtiter plates (high binding; Costar)
were coated with 50 l of antigen/well. The antigens used
follow: antigens JL8 (1,000 ng ml1), MAP (200 ng ml1), and
TcPo (200 ng ml1) alone; mixtures of two antigens, such as
JL8 and MAP (JM) (250 ng ml1), MAP and TcPo (MT), and
JL8 and TcPo (JT) (300 ng ml1); or all three antigens to-
gether, namely, MAP, JL8, and TcPo (MJT) (350 ng ml1).
Titration of antigen binding to microtiter plates was performed
by recombinant proteins labeled with iodine (125I), as previ-
ously described (29). Higher average absorbance (A492) (mean
 standard deviation [SD]) and sensitivity values were ob-
tained with JL8 (0.89  0.41 and 100%, respectively), followed
by MAP (0.85 0.56 and 82%, respectively) and TcPo (0.56
0.42 and 73%, respectively) (Fig. 1A). Using different combi-
nations of antigens in ELISAs resulted in a sensitivity of 100%,
with higher reactivities than those of the single recombinant
antigens. The reactivities of the antigen combinations were
1.34  0.50 for JM, 1.19  0.59 for MT, and 1.17  0.48 for
MJT. BHF and EAE-ELISA had a sensitivity of 100%, with
averages of 1.26 0.42 and 1.13 0.22, respectively (Fig. 1A).
The JT combination had a low sensitivity (not shown), so its
use was discontinued.
Some mixtures of recombinant proteins also detect anti-T.
cruzi IgG antibodies from acute-phase patients. The capacities
of mixtures of recombinant antigens (JM, MT, and MJT) to
detect acute-phase antibodies were tested. JM and MJT were
able to detect 84.2% and MT was able to detect 78.9% of acute
cases (9 samples from Panama and 10 from Brazil) (Table 1
and Fig. 1B). JL8 and MAP antigens are made up of 14- and
38-amino-acid repeats, respectively, that are strongly con-
served in strains and isolates of T. cruzi (11, 15), which im-
proved the sensitivity of diagnosis of acutely infected individ-
uals. These results were quite similar to those described for
recombinant SAPA (shed acute-phase antigen) that has been
employed in the diagnosis of the acute phase of Chagas’ dis-
ease (2, 7, 16, 20); its sensitivity varied from 80.8 to 90% (2,
16). The specificities for acute-phase sera were 15.8% by BHF,
94.7% by EAE-ELISA (Table 2 and Fig. 1B), and 100% by
TESA blotting (IgG and IgM [not shown]).
Mixtures of recombinant proteins are more specific than
whole-epimastigote antigens. The specificities of recombinant
mixtures were determined with sera from 142 nonchagasic
individuals (62 of these individuals had other diseases) (Table
2). The specificities of JM, MT, and MJT recombinant proteins
were 99.3, 96.5, and 98.6%, respectively (Table 2). BHF and
TESA blotting presented specificities of 99.3 (Table 2) and
100% (not shown), respectively. The sensitivity of EAE was
95.8%, since 6 of 10 sera from patients with leishmaniasis
showed a cross-reaction (Table 2). The cross-reactivity of sera
from individuals infected with Trypanosoma rangeli in CSC
tests has been the subject of controversy (32), but our samples
from T. rangeli-infected individuals were not reactive in assays
that use T. cruzi recombinant proteins or in CSC tests.
Evaluation of the JM mixture to diagnose T. cruzi-infected
individuals from different geographical areas. The JM mixture
gave a sensitivity of 99.3% (Table 2 and Fig. 2) with sera from
FIG. 1. (A) Reactivity data of T. cruzi recombinant antigens MAP, JL8, and TcPo individually or in various combinations of two or three
proteins (JM, MT, and MJT) with sera from 11 Brazilian patients with well-defined chronic-phase Chagas’ disease. (B) Reactivity data of
recombinant mixtures JM, MT, MJT, and BHF with 19 acute-phase sera. The sensitivities of the different antigens or tests are shown at the bottom
of the figure. EAE-ELISA data are shown in panels A and B. For each antigen, the average is indicated by the short horizontal line, and the arrow
indicates the cutoff value.
TABLE 1. Geographical origin and distribution of serum samples
of T. cruzi-infected individuals and nonchagasic individuals
Country
No. of
serum
samples
No. of individuals
T. cruzi infected Nonchagasic
Acute
phase
Chronic
phase
Other
diseases Healthy
Bolivia 51 0 15 0 36
Brazil 172 10 81 53 28
Honduras 40 0 35 0 5
Mexico 5 0 3 0 2
Panama 38 9 20 9 0
Venezuela 16 0 7 0 9
Total 322 19 161 62 80
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chagasic individuals (n  150) (Table 1) that showed a sensi-
tivity of 100% in three CSC tests (not shown) and with EAE-
ELISA (Table 2). The average absorbance ( SD) or reactivity
obtained with JM was high for chagasic patients from Bolivia
(1.54  0.33), Brazil (1.50  0.63), Honduras (1.67  0.59),
and Mexico/Venezuela (1.58  0.62) but low for Panama (0.75
 0.64) (Fig. 2). The sensitivity presented by JM (99.4%) was
similar to those described with mixtures of recombinant anti-
gens and/or synthetic peptides (4, 10, 20, 21, 31). Notwith-
standing the fact that several reports have reported greater
diagnostic ability of recombinant protein mixtures, there are
always a few chagasic patients in whom anti-T. cruzi antibodies
were not detected or the reactivity was near the cutoff value
(10, 20, 21, 24, 31). This could be due to the heterogeneity of
different parasite strains and/or variability in individual host
immune responses. In conclusion, our results show that recom-
binant proteins in mixtures, such as JM, are very useful as
antigens for immunodiagnosis of acute and chronic Chagas’
disease and that the specificity was superior to that of CSC
tests that employ whole or semipurified fractions from epimas-
tigote forms of T. cruzi.
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